Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
#DYK? We’re putting our 90-year experience to good use, by helping provide access to epilepsy care in low- and middle-income countries, overcoming many infrastructural and institutional barriers to do so. #UCB90 ???? Find out more here: https://t.co/n49
— UCB News (@ucb_news) 14.09.2018 -
This year has been one of the most ambitious for UCB in immuno-dermatology, and our commitment to this community can be clearly seen at #EADV2018. Learn more: https://t.co/L8dqhi5jdo https://t.co/g0PptxDKZp
— UCB News (@ucb_news) 13.09.2018 -
Great insights from UCB’s U.S. head of neurology Mike Davis, collected during @PracticalNeuro RoundTable discussion! https://t.co/ey4weoiYyt
— UCB News (@ucb_news) 13.09.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
